CD56阳性老年急性髓系白血病患者的临床特征及预后分析

Clinical Features and Prognosis of the Elderly with Acute Myeloid Leukemia of Positive CD56

中文关键词: 老年  急性髓系白血病  CD56

英文关键词: elderly  acute myeloid leukemia  CD56

中文摘要:

      目的 探讨老年急性髓系白血病(acute myeloid leukemia,AML)患者CD56表达水平及预后意义.方法 回顾性分析江苏省人民医院血液科118例初诊＞60岁AML患者CD56的表达情况,比较CD56阳性(n =24例)和CD56阴性(n=94例)患者的临床特征、治疗效果及生存时间.结果 除细胞遗传学因素外,CD56阳性和CD56阴性患者在年龄、性别、FAB分型、初诊时白细胞计数、血红蛋白、血小板计数及骨髓原始细胞计数方面均无统计学意义(P＞0.05);CD56阳性与CD56阴性患者诱导1个疗程后CR率(58.3％ vs 54.3％,P=0.720)和OR率(75％ vs 64.9％,P=0.348)没有明显差异,但CD56阴性患者的中位OS明显长于CD56阳性患者(18个月vs9个月,P=0.026).多因素Cox回归提示年龄＞70岁、首次诱导后CR及CD56阳性是老年AML患者的独立预后因素.结论 CD56可能是老年初诊AML预后不良的标记之一.

英文摘要:

      Objective To explore the expression and prognostic significance of CD56 in elderly patients with acute myeloid leukemia (AML).Methods A retrospective analysis was made to the expression of CD56 in 118 patients ≥60 years old newly diagnosed to be with AML,and the clinical features,curative effect and overall survival (OS) of 24 patients in positive CD56 group and 94 patients in negative CD56 group were compared.Results There existed no statistical difference in age,sex,FAB classification,white blood cell count,hemoglobin,platelet count and bone marrow count between the 2 groups (P＞0.05);the complete remission (CR) rates and the overall survival (OS) rates of the patients in the 2 groups after 1 course of induction were of no statistical difference [(58.3％ vs 54.3％,P=0.720),(75％ vs 64.9％,P=0.348)] while the medium OS rate of the patients in negative CD56 group was much longer than that of the patients in positive CD56 group (18 months vs 9 months,P=0.026);Multivariate Cox analysis indicated that age ≥ 70 years old,CR rate and positive CD56 after the initial induction were the independent prognostic factors.Conclusions CD56 may be one of the markers of poor prognosis in the elderly with newly diagnosed AML.